Oncolytics Biotech Inc. — FY2022 Form 20-F
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter report; quarterly financial results are not provided in the supplied filing text. Financial amounts below are in Canadian dollars unless noted. The company reports under IFRS.
Business context
Oncolytics is a clinical-stage biopharmaceutical company developing pelareorep, an intravenously delivered oncolytic reovirus intended to stimulate anti-tumor immune responses. Its principal development priorities are HR+/HER2- metastatic breast cancer and advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), with additional gastrointestinal cancer studies. Pelareorep is not approved for commercial sale, and the company has no established product revenue.
Financial and liquidity highlights
| Metric | FY2022 / Dec. 31, 2022 | Comparator |
|---|---|---|
| Revenue | No operating revenue reported; no revenue was recognized from the Adlai licensing contract in 2022 | Contract liability remained $6.73 million, expected to be recognized over the next five years |
| Research and development expense | $15.43 million | $12.92 million in 2021 |
| General and administrative expense | $11.49 million | $13.32 million in 2021 |
| Net loss | $24.84 million; loss per share $0.43 | $26.30 million and $0.49 per share in 2021 |
| Cash used in operating activities | $23.36 million | $22.43 million in 2021 |
| Cash and cash equivalents | $11.67 million | $41.26 million at Dec. 31, 2021 |
| Marketable securities | $20.47 million | None reported at Dec. 31, 2021 |
| Total assets / shareholders’ equity | $37.33 million / $26.50 million | $45.88 million / $36.10 million at Dec. 31, 2021 |
| Debt and lease liabilities | No long-term debt; lease liabilities totaled $0.37 million | Accounts payable and accrued liabilities were $3.65 million |
Cash, cash equivalents and marketable securities totaled $32.14 million at year-end. Management said existing resources were sufficient for at least the next 12 months of presently planned operations, while also anticipating a need for future financing. The company reported an accumulated deficit of $418.25 million. It has no stated gross margin because it has no commercial product sales.
Changes versus the prior year
- Net loss narrowed by about $1.47 million, while loss per share improved from $0.49 to $0.43.
- R&D expense rose by about $2.51 million, including higher clinical trial, manufacturing and personnel costs. G&A expense fell by about $1.82 million, mainly alongside lower public-company-related and share-based compensation costs.
- Operating cash use increased by about $0.92 million. Total cash and marketable securities declined from $41.26 million at 2021 year-end to $32.14 million at 2022 year-end; cash also shifted into marketable securities during 2022.
- The company raised $12.57 million net through its at-the-market (ATM) equity distribution agreement in 2022 and issued 6.24 million shares through that agreement. Year-end shares outstanding increased from 55.04 million to 61.33 million.
Outlook, clinical developments and risks
- Outlook: No quantified revenue or earnings guidance is provided. Management expects substantial losses to continue and plans to advance breast cancer and PDAC programs toward Phase 3 licensure-enabling studies, subject to clinical progress, financing, regulatory requirements and partner support.
- PDAC: Interim GOBLET results reported an objective response rate of 69% and clinical benefit rate of 85% in 13 patients. The cohort met its Stage 1 response threshold; management said a Stage 2 expansion would not be necessary. The FDA granted Fast Track designation for pelareorep with atezolizumab, gemcitabine and nab-paclitaxel in advanced/metastatic PDAC. These are interim results, not evidence of approval or definitive efficacy.
- Breast cancer: BRACELET-1 enrollment concluded in 2022, with follow-up and endpoint analyses continuing. Adlai reported interim bridging-trial results in China, including a 50% partial response rate among 14 evaluable patients and median progression-free survival of 9.1 months at the data cutoff; the results were preliminary.
- Funding and dilution: Continued development depends on additional capital, partnerships or other financing. Equity financing could dilute shareholders. The company renewed a shelf prospectus qualifying up to $150 million of securities and had an ATM agreement in place. From January 1 to March 2, 2023, it issued 1,499,044 shares for gross proceeds of US$2.57 million through the ATM.
- Execution and supply risks: Clinical outcomes, enrollment, regulatory decisions and access to third-party checkpoint inhibitors are uncertain. The company depends on external manufacturers, CROs, clinical sites and specialized supplies; disruption could delay trials. It disclosed approximately $16.78 million of clinical-trial and manufacturing commitments, mainly over the next three years, most cancellable with notice.
- External and other risks: COVID-19-related enrollment and supply-chain delays and the Ukraine conflict affected operations and market uncertainty; management said the impact to date was not significant. Other material risks include adverse effects, competition, intellectual-property challenges, reliance on Adlai for specified Asian territories, foreign-exchange exposure and potential future financing constraints.
- Tax and governance: The company believes it was a passive foreign investment company (PFIC) in 2022 and expects PFIC status in the current tax year, potentially creating adverse U.S. tax consequences. Management assessed internal control over financial reporting as effective; the auditor did not provide an attestation because the company is a non-accelerated filer.
Most important facts for investors to verify
- Progress, final results and regulatory plans for GOBLET, BRACELET-1 and the PDAC and breast cancer programs; distinguish interim findings from confirmed, mature data.
- Cash runway assumptions and subsequent financing needs, including ATM usage, shelf capacity and dilution from future share issuance.
- Clinical, manufacturing and other committed cash requirements, and whether the reported commitments or trial schedules have changed.
- Whether Adlai achieves development milestones and whether any licensing royalties or milestone payments become payable.
- Current PFIC status and availability of information needed by U.S. shareholders for any tax elections.
- The audited statements report an unmodified IFRS audit opinion and no critical audit matters; confirm these details against the complete filing and subsequent reports.